Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 5;9(10):e003371. doi: 10.1136/jitc-2021-003371

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

The landscape of HLA-I LOH statuses in TNBCs. (A) Summary of characteristics of HLA-I LOH and HLA-I non-LOH. (B) Distribution of HLA-I LOH and HLA-I non-LOH. (C) Distribution of the TNBC immune subtype and TNBC intrinsic subtype (FUSCC TNBC subtype). (D) Comparison of Kaplan-Meier curves of RFS between HLA-I non-LOH and LOH patients. (E) Kaplan-Meier curves of RFS between the HLA-I non-LOH and LOH groups in immune-inflamed patients and non-immune-inflamed patients. (F) Kaplan-Meier curves of RFS between immune-inflamed patients and non-immune-inflamed patients with or without HLA-I LOH. BLIS, basal-like and immune-suppression; CNA, copy number alteration; HLA, human leukocyte antigen; IM, immunomodulatory; LAR, luminal androgen receptor; LOH, loss of heterozygosity; MES, mesenchymal-like; ns, no significance; RFS, relapse-free survival; TNBCs, triple-negative breast cancers; ***p<0.001.